NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

175.60B

Vuru Grade

69.64/100

Current Price

$73.97
-0.36 (-0.48%)

Growth Price

$56.21
Overvalued by 24.01%

Stability Price

$14.62
Overvalued by 80.23%

Company Metrics

  • P/E 10.14
  • P/S 3.5
  • P/B 2.29
  • EPS 7.3
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.72 / 3.57%
  • Avg. Vol. 2.41M
  • Shares 2.37B
  • Market Cap. 175.60B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Pfizer Inc, Sanofi SA (ADR), Novartis AG (ADR): Who Will Acquire Medivation Inc?
Business Finance News - May 4, 2016
As the merger and acquisition (M&A) spree is booming, multiple pharmaceutical companies have put Medivation Inc. (NASDAQ:MDVN) on the top of their acquisition list.
Novartis AG (ADR) Under Pressure on Q1 Revenue Decline
Bidness ETC - Apr 21, 2016
Novartis AG (ADR) (NYSE:NVS) has reported financial results for the first quarter of fiscal year 2016 (1QFY16) with a decline in both, its earnings and revenues.
Novartis AG (ADR) (NYSE:NVS): Big Market Mover
Street Report - Apr 26, 2016
[Market Realist] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) reported a rise of ~1% in its revenue on a constant currency basis in its 1Q16 earnings.
Novartis AG (ADR) First-Quarter Earnings: What to Expect?
Bidness ETC - Apr 20, 2016
Novartis AG (ADR) (NYSE:NVS) is set to announce its financial results for the first quarter of 2016 (1Q) on Thursday, April 21.
Earnings per Share Report: Novartis AG (ADR) (NYSE:NVS)
News Oracle - 17 hours ago
Last Trade: The Company fell -2.34% and finished at $74.33. The daily volume was measured at 2.17 million shares. The 52-week high of the share price is $106.84 and the 52-week low is $69.89.
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Market Exclusive - Mar 25, 2016
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Novartis AG (ADR) (NYSE:NVS) Doles Out Over $25 Million In The Wake Of Bribery ... - Sonoran Weekly Review
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Business Finance News - Nov 23, 2015
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Novartis AG (ADR) And Roche May Have To Wait Longer For “Outcome-Based ...
Business Finance News - Nov 13, 2015
The outcome-based drug pricing model is becoming a dream for Novartis AG (ADR) (NYSE:NVS) and Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY).
Novartis AG (ADR) Entresto Clinches EU approval
Business Finance News - Nov 25, 2015
Novartis Pharmaceuticals UK's Chief Scientific Officer, Dimitrios Georgiopoulos, says, “Heart failure is a life-threatening condition that leaves a major impact on patients and their carers.
Novartis Gets EU Approval for Cardiovascular Drug Entresto - Zacks.com
Trade of the Day: NVS Stock Not Making the Cut – Sell Now
Investorplace.com - Oct 1, 2015
Novartis AG (ADR) (NVS) - This company is a leading provider of pharmaceuticals, generic drugs and health care products for consumers and animals.